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Background -Whilst much is known of the outcome of lung transplantation for patients with cystic fibrosis, less is known about those patients who are either not referred for transplantation or who die before a donor is available. The referral practice and outcome of all the cystic fibrosis patients in one clinic was documented, whether or not they were assessed for lung transplantation. The results give a perspective on the impact of the current transplantation programmes on the adult cystic fibrosis population as a whole. The outcome for all the patients referred 5 from our clinic is shown in fig 1. One patient 14 was considered unsuitable by the cardiothoracic centre for heart-lung transplantation because of colonisation with multiply resistant 10 Staphylococcus aureus and another deteriorated rapidly and died whilst awaiting assessment. In all, 47 patients were accepted onto either the active transplantation list or a provisional list. The waiting time between referral and assessment varied between one and 20 months with an average of 6-6 months and a mode of four months (fig 2) . The very long delays in three patients were due to two patients changing their mind twice and cancelling appointments for assessment and in one case the assessment form was misplaced.
At initial assessment 24 of the 47 patients accepted were put on to a provisional list and kept under regular review. Subsequently, 17 of these patients joined the active transplantation list. The average length of time on the nonactive list was 12X7 months (24-7 months for those remaining on the list and 6-4 months for those who later joined the active list). Two 3L patients declined rapidly and died whilst on 20 the non-active list.
Fourteen patients on the active waiting list for transplantation died. Sadly, 14 of our patients died whilst awaiting their transplant and two deteriorated quickly and died on the non-active list. Thus, 16 of the 47 patients (34%) accepted for transplantation died before the operation and, in our opinion, all remained eligible for transplantation until shortly before death.
Survival after transplantation for cystic fibrosis in our group was 58% at one year and 52% at two and three years. This is less than that reported from the transplant centres themselves. At Papworth survival was 78% at one year and 65% at three years. 7 Results from Harefield were 69%, 52%, and 49% at one, two and three years, respectively.8 A small North American study reported 78% survival at one and three years.9 Direct comparisons between these series and our own is difficult for three reasons: the Harefield and Papworth series contain some Birmingham patients; the other studies quote survival for adults and children; and, lastly, the numbers are relatively small and premature death or prolonged survival in a few patients can have a large effect on the survival rate. Bearing these caveats in mind, it appears that the main reason for lower survival in our group is a high early mortality. We had a higher proportion of patients with B cepacia in their sputum before transplantation than was quoted in other series. 8 Three of the four patients with B cepacia who were transplanted died within one month with B cepacia septicaemia. Snell in Toronto found that seven of 15 patients who grew B cepacia either before or after transplantation also died as a direct result of overwhelming B cepacia infection, whereas there were no deaths amongst seven patients who had never grown B cepacia.'0 This contrasts with data from the UK centres that suggest that there is no excess risk of death following transplantation when colonised by B cepacia. l This difference may be due to the earlier occurrence of the epidemic strain in North America, as it is only within the past year that substantial numbers of the British cohort of cystic fibrosis patients colonised by the epidemic strain of B cepacia have required transplantation. Indeed, in our small group the first transplant in a patient colonised by B cepacia in 1990 was successful whereas the three patients transplanted since 1993 have all died.
A major concern is when patients deteriorate and a decision has to be made to continue with intensive medical therapy or to "switch" to palliative care. The counselling process which takes place before referral for transplantation needs to include a realistic appreciation of the risks as well as the great benefits of a successful outcome. Physicians need to be mindful that patients may pass through their "window of opportunity" and be prepared to provide support and comfort before their patient's death. Whether to ventilate such patients in the hope that a transplant will be available in the immediate future is a complex issue and is best discussed with the transplantation centre and the patient. In our experience this has been a fruitless exercise. The temptation to "keep going" may deny a dying patient comfort and time to accept death.
Lung transplantation provides new hope for cystic fibrosis patients with progressive deterioration in lung function. Many patients will not live long enough to be found a suitable donor because of competition for a limited supply of organs. In these circumstances patients and staff need to be informed of the likely outcome for all patients awaiting lung transplantation.
